Cognition Therapeutics Initiates Public Offering of Common Stock to Advance Neurodegenerative Disorder Treatments
PURCHASE, N.Y. – Cognition Therapeutics, a leading biopharmaceutical company focused on developing treatments for neurodegenerative disorders, has announced the launch of an underwritten public offering of its common stock. The company aims to raise funds to further advance its innovative therapies for conditions such as Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration.
The offering includes an option for the underwriter to purchase additional shares, providing flexibility for potential investors. Titan Partners Group, a division of American Capital Partners, will serve as the sole book-running manager for the offering, which will be conducted under a shelf registration statement filed with the SEC.
Cognition Therapeutics is at the forefront of developing novel therapies, with its lead candidate CT1812 currently in clinical trials. The company’s portfolio of σ-2 receptor modulators shows promise in regulating pathways affected in neurodegenerative diseases, offering hope for patients and caregivers.
While the completion of the offering is subject to market conditions, Cognition Therapeutics remains optimistic about the potential impact of its research and development efforts. Investors can access detailed information about the offering through the SEC’s website or by contacting Titan Partners Group.
As the company moves forward with its mission to address the unmet needs of patients with neurodegenerative disorders, the public offering represents a significant step in advancing groundbreaking treatments. Stay tuned for updates on Cognition Therapeutics’ progress in the fight against these devastating conditions.
